Literature DB >> 23176217

The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap.

Kouichi Tamura1, Hiromichi Wakui, Akinobu Maeda, Toru Dejima, Masato Ohsawa, Kengo Azushima, Tomohiko Kanaoka, Sona Haku, Kazushi Uneda, Shin-ichiro Masuda, Koichi Azuma, Atsu-ichiro Shigenaga, Yuichi Koide, Yuko Tsurumi-Ikeya, Miyuki Matsuda, Yoshiyuki Toya, Yasuo Tokita, Akio Yamashita, Satoshi Umemura.   

Abstract

The Ang II type 1 receptor (AT1R)-associated protein (ATRAP/Agtrap) is a molecule specifically interacting with the carboxyl- terminal domain of AT1R. The results of in vitro studies showed that ATRAP suppresses Ang II-mediated pathological responses in cardiovascular cells by promoting AT1R internalization. With respect to the tissue distribution and regulation of ATRAP expression in vivo, ATRAP is broadly expressed in many tissues as is AT1R. Accumulating evidence indicates that a tissue-specific regulatory balancing of ATRAP and AT1R expression may be involved in the modulation of AT1R signaling at local tissue sites and also in the pathophysiology of hypertension and its associated end-organ injury. Furthermore, the activation of ATRAP in transgenic-models inhibited inflammatory vascular remodeling and cardiac hypertrophy in response to Ang II stimulation. These results suggest the clinical potential benefit of an ATRAP activation strategy in the treatment of hypertension and related organ injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23176217     DOI: 10.2174/1381612811319170010

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  17 in total

Review 1.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 2.  ATRAP, a receptor-interacting modulator of kidney physiology, as a novel player in blood pressure and beyond.

Authors:  Kouichi Tamura; Kengo Azushima; Sho Kinguchi; Hiromichi Wakui; Takahiro Yamaji
Journal:  Hypertens Res       Date:  2021-10-12       Impact factor: 3.872

3.  Age-Related Expression of Human AT1R Variants and Associated Renal Dysfunction in Transgenic Mice.

Authors:  Sudhir Jain; Anita Rana; Kavita Jain; Sravan K Perla; Nitin Puri; Ashok Kumar
Journal:  Am J Hypertens       Date:  2018-10-15       Impact factor: 2.689

4.  Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein.

Authors:  Miyuki Matsuda; Kouichi Tamura; Hiromichi Wakui; Akinobu Maeda; Masato Ohsawa; Tomohiko Kanaoka; Kengo Azushima; Kazushi Uneda; Sona Haku; Yuko Tsurumi-Ikeya; Yoshiyuki Toya; Yohei Maeshima; Akio Yamashita; Satoshi Umemura
Journal:  J Biol Chem       Date:  2013-05-07       Impact factor: 5.157

5.  Renal tubule angiotensin II type 1 receptor-associated protein promotes natriuresis and inhibits salt-sensitive blood pressure elevation.

Authors:  Hiromichi Wakui; Kazushi Uneda; Kouichi Tamura; Masato Ohsawa; Kengo Azushima; Ryu Kobayashi; Kohji Ohki; Toru Dejima; Tomohiko Kanaoka; Yuko Tsurumi-Ikeya; Miyuki Matsuda; Kotaro Haruhara; Akira Nishiyama; Machiko Yabana; Tetsuya Fujikawa; Akio Yamashita; Satoshi Umemura
Journal:  J Am Heart Assoc       Date:  2015-03-19       Impact factor: 5.501

6.  Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesity.

Authors:  Akinobu Maeda; Kouichi Tamura; Hiromichi Wakui; Toru Dejima; Masato Ohsawa; Kengo Azushima; Tomohiko Kanaoka; Kazushi Uneda; Miyuki Matsuda; Akio Yamashita; Nobuko Miyazaki; Keisuke Yatsu; Nobuhito Hirawa; Yoshiyuki Toya; Satoshi Umemura
Journal:  J Am Heart Assoc       Date:  2013-07-31       Impact factor: 5.501

7.  Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high‑fat‑fed spontaneously hypertensive rats.

Authors:  Tingjun Wang; Guili Lian; Xiaoqi Cai; Zhihong Lin; Liangdi Xie
Journal:  Mol Med Rep       Date:  2017-11-15       Impact factor: 2.952

8.  Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders.

Authors:  Akinobu Maeda; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Tomohiko Kanaoka; Ryu Kobayashi; Kohji Ohki; Miyuki Matsuda; Yuko Tsurumi-Ikeya; Akio Yamashita; Yasuo Tokita; Satoshi Umemura
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

9.  Effects of Ang II receptor blocker irbesartan on adipose tissue function in mice with metabolic disorders.

Authors:  Akinobu Maeda; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Yuko Tsurumi-Ikeya; Tomohiko Kanaoka; Toru Dejima; Koji Ohki; Sona Haku; Akio Yamashita; Satoshi Umemura
Journal:  Int J Med Sci       Date:  2014-04-27       Impact factor: 3.738

10.  Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension.

Authors:  Masato Ohsawa; Kouichi Tamura; Hiromichi Wakui; Akinobu Maeda; Toru Dejima; Tomohiko Kanaoka; Kengo Azushima; Kazushi Uneda; Yuko Tsurumi-Ikeya; Ryu Kobayashi; Miyuki Matsuda; Shinichi Uchida; Yoshiyuki Toya; Hiroyuki Kobori; Akira Nishiyama; Akio Yamashita; Yoshihiro Ishikawa; Satoshi Umemura
Journal:  Kidney Int       Date:  2014-04-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.